Arcutis Biotherapeutics Q4 Preview Forecasts $22M Revenue, Roflumilast Update
Arcutis Biotherapeutics will report Q4 2025 results on February 25, with analysts forecasting $22 million in revenue and an EPS loss of $0.57. Investors will focus on ZORYVE’s net product revenue ramp and an update on the late-stage roflumilast atopic dermatitis trial.
1. Earnings Date and Access
Arcutis Biotherapeutics has set its Q4 2025 earnings release for February 25, with a conference call to follow after market close. Investors can access the webcast via the company’s investor relations website.
2. Analyst Estimates and Financial Forecast
Consensus forecasts call for $22 million in quarterly revenue, representing a sequential sales increase driven by ZORYVE uptake, and an EPS loss of $0.57. These estimates will be a key reference point for gauging commercial momentum.
3. Key Commercial and Pipeline Catalysts
Attention will center on ZORYVE net product revenue growth as dermatology uptake expands. Management is also expected to provide an update on the phase 3 roflumilast topical trial for atopic dermatitis, a pivotal catalyst for 2026.